WASHINGTON and ATLANTA – LexisNexis® Risk Solutions today announced its Risk Defense Platform (RDP) has been certified by SAFE-BioPharma as compliant with the National Institute of Standards and Technology (NIST) SP 800-63A guidelines at Identity Assurance Level 2 (IAL2). The NIST guidelines provide technical requirements for federal agencies implementing digital identity services.
SAFE-BioPharma is a U.S. Trust Framework Provider that certifies technologies and practices used by identity credential issuers. The new certification enables federal agencies to deploy the LexisNexis® Risk Defense Platform suite of identity proofing solutions with confidence that they meet the highest levels of identity fraud protection. NIST 800-63A certification means that the LexisNexis Risk Defense Platform can be trusted and used at known levels of assurance by U.S. federal entities.
“Federal agencies need more robust identity proofing capabilities to combat the constantly-evolving identity theft and fraud schemes that cost millions of dollars annually,” said Haywood Talcove, CEO, Government, LexisNexis Risk Solutions. “With NIST 800-63A certification and the release of Gartner’s Market Guide for Identity Proofing and Corroboration and the inclusion of the Risk Defense Platform, we believe LexisNexis Risk Solutions provides the highest level of protection to help ensure that people who interact with and/or do business with government agencies are securely credentialed and bound to their real-world identities.”
The LexisNexis Risk Defense Platform is a full suite of identity proofing solutions that can be accessed through a single system, giving government agencies the flexibility to verify identities and self-reported information. It provides a configurable policy decision engine designed to help government agencies manage complex fraud and identity rules, while reining in the operational resources needed to defend against fraud.
With NIST 800-63A IAL2 identity assurance level certification, the LexisNexis Risk Defense Platform supports a variety of acceptable identity proofing techniques to improve user adoption, decrease false negatives and discern between a real user and a fraudster.
To read Gartner’s Market Guide for Identity Proofing and Corroboration, download a complimentary copy at http://solutions.lexisnexis.com\gartnerguide.
For more information about the SAFE-BioPharma/NIST 800-63A certification, visit http://www.safe-biopharma.org/. To learn more about NIST-certified solutions including the Risk Defense Platform, please visit https://risk.lexisnexis.com/products/risk-defense-platform.
Attribution: Gartner, Market Guide for Identity Proofing and Corroboration, Tricia Phillips, Jonathan Care, Danny Luong, Ant Allan, 24 April 2018
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About LexisNexis Risk Solutions
LexisNexis Risk Solutions harnesses the power of data and advanced analytics to provide insights that help businesses and governmental entities reduce risk and improve decisions to benefit people around the globe. We provide data and technology solutions for a wide range of industries including insurance, financial services, healthcare and government. Headquartered in metro Atlanta, Georgia, we have offices throughout the world and are part of RELX (LSE: REL/NYSE: RELX), a global provider of information and analytics for professional and business customers across industries. For more information, please visit www.risk.lexisnexis.com and www.relx.com.